Digestive Diseases and Sciences

, Volume 58, Issue 2, pp 414–422 | Cite as

Enhanced RegIV Expression Predicts the Intrinsic 5-Fluorouracil (5-FU) Resistance in Advanced Gastric Cancer

  • Li-Sha Ying
  • Jiang-Liu Yu
  • Xiao-Xiao Lu
  • Zhi-Qiang Ling
Original Article



RegIV, a member of the Regenerating (REG) gene family, may be a marker for the prediction of resistance to 5-fluorouracil (5-FU)-based chemotherapy. However, the relationship between the intrinsic drug resistance of gastric cancer (GC) cells to 5-FU used alone (single FU) or in multidrug therapeutic regimens (5-FU combinations) and RegIV expression has not been investigated.


The patient cohort comprised 45 patients with primary GC. The chemoresistance of GC cells to therapeutic regimens consisting of single 5-FU or FU combinations was investigated using the ATP-tumor chemosensitivity assay. The level of RegIV mRNA transcripts was determined by real-time reverse transcriptase-PCR. RegIV expression was evaluated as a novel predictive biomarker for the intrinsic drug resistance of primary GC cells to single 5-FU or 5-FU combinations.


Upregulation of RegIV mRNA transcripts was observed in 36 of the 45 tumor specimens and was positively correlated with the invasive depth of the tumor cells (p = 0.000), the clinical stages (p = 0.000) and the in vitro intrinsic drug resistance of primary GC cells to 5-FU (p = 0.000) or 5-FU combinations.


RegIV mRNA transcript level was strongly associated with the intrinsic resistance of GC cells to single 5-FU or 5-FU combinations, suggesting that RegIV may play an important role in the intrinsic resistance of GC cells to 5-FU and that targeted therapy against the RegIV gene could be applied to overcome 5-FU resistance in the treatment of GC.


Gastric cancer Regenerating islet-derived family, member 4 (RegIV5-Fluorouracil ATP-tumor chemosensitivity assay Real-time reverse transcriptase-PCR 



This research was partly supported by a grant from the Science and Technology General Project of Zhejiang Province (No. 2009C33143) and a grant from the Science and Technology Plan Projects of Zhejiang Provincial Medicine and Health (2009B029).

Conflict of interest



  1. 1.
    Treatment Architecture China: Gastric Cancer. KantarHealth and Draco Healthcare Consulting, LLC; 2009.Google Scholar
  2. 2.
    MattsonJack. CancerMPact. The Mattson Jack Group, Inc.; St. Louis, MO. 2009.Google Scholar
  3. 3.
    Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893–1907.CrossRefPubMedGoogle Scholar
  4. 4.
    Nomura S, Kaminishi M. Surgical treatment of early gastric cancer. Dig Surg. 2007;24:96–100.CrossRefPubMedGoogle Scholar
  5. 5.
    Jain VK, Cunningham D, Chau I. Preoperative and postoperative chemotherapy for gastric cancer. Surg Oncol Clin N Am. 2012;21:99–112.CrossRefPubMedGoogle Scholar
  6. 6.
    Dikken JL, van de Velde CJ, Coit DG, Shah MA, Verheij M, Cats A. Treatment of resectable gastric cancer. Therap Adv Gastroenterol. 2012;5:49–69.CrossRefPubMedGoogle Scholar
  7. 7.
    Meyer HJ, Wilke H. Treatment strategies in gastric cancer. Dtsch Arztebl Int. 2011;108:698–705.PubMedGoogle Scholar
  8. 8.
    Pasini F, Fraccon AP, DE Manzoni G. The role of chemotherapy in metastatic gastric cancer. Anticancer Res. 2011;31:3543–3554.PubMedGoogle Scholar
  9. 9.
    Fedorenko IV, Paraiso KH, Smalley KS. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol. 2011;82:201–209.CrossRefPubMedGoogle Scholar
  10. 10.
    Shekhar MP. Drug resistance: challenges to effective therapy. Curr Cancer Drug Targets. 2011;11:613–623.CrossRefPubMedGoogle Scholar
  11. 11.
    Mackenzie M, Spithoff K, Jonker D. Systemic therapy for advanced gastric cancer: a clinical practice guideline. Curr Oncol. 2011;18:e202–e209.CrossRefPubMedGoogle Scholar
  12. 12.
    Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today. 2010;40:295–300.CrossRefPubMedGoogle Scholar
  13. 13.
    Ling ZQ, Qi CJ, Lu XX, et al. Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumor chemosensitivity assay. Acta Pharmacol Sin. 2012;33:401–406.CrossRefPubMedGoogle Scholar
  14. 14.
    Koomen JM, Smalley KS. Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma. Oncotarget. 2011;2:329–335.PubMedGoogle Scholar
  15. 15.
    Sumantran VN. Cellular chemosensitivity assays: an overview. Methods Mol Biol. 2011;731:219–236.CrossRefPubMedGoogle Scholar
  16. 16.
    Blumenthal RD, Goldenberg DM. Methods and goals for the use of in vitro and in vivo chemosensitivity testing. Mol Biotechnol. 2007;35:185–197.CrossRefPubMedGoogle Scholar
  17. 17.
    Kurbacher CM, Cree IA. Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements. Methods Mol Med. 2005;110:101–120.PubMedGoogle Scholar
  18. 18.
    Quintieri L, Fantin M, Vizler C. Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs. Adv Exp Med Biol. 2007;593:95–104.CrossRefPubMedGoogle Scholar
  19. 19.
    Violette S, Festor E, Pandrea-Vasile I, et al. Reg IV a new member of the regenerating gene family, is overexpressed in colorectal carcinomas. Int J Cancer. 2003;103:185–193.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhang Y, Lai M, Lv B, et al. Overexpression of Reg IV in colorectal adenoma. Cancer Lett. 2003;200:69–76.CrossRefPubMedGoogle Scholar
  21. 21.
    Bishnupuri KS, Luo Q, Murmu N, Houchen CW, Anant S, Dieckgraefe BK. Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas. Gastroenterology. 2006;130:137–149.CrossRefPubMedGoogle Scholar
  22. 22.
    Li XH, Zheng Y, Zheng HC, et al. REG IV overexpression in an early stage of colorectal carcinogenesis: an immunohistochemical study. Histol Histopathol. 2010;25:473–484.PubMedGoogle Scholar
  23. 23.
    Heiskala K, Arola J, Heiskala M, Andersson LC. Expression of Reg IV and Hath1 in neuroendocrine neoplasms. Histol Histopathol. 2010;25:63–72.PubMedGoogle Scholar
  24. 24.
    Tamura H, Ohtsuka M, Washiro M, et al. Reg IV expression and clinicopathologic features of gallbladder carcinoma. Hum Pathol. 2009;40:1686–1692.CrossRefPubMedGoogle Scholar
  25. 25.
    Hayashi T, Matsubara A, Ohara S, et al. Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker. Oncol Rep. 2009;21:95–100.PubMedGoogle Scholar
  26. 26.
    Sasahira T, Oue N, Kirita T, et al. Reg IV expression is associated with cell growth and prognosis of adenoid cystic carcinoma in the salivary gland. Histopathology. 2008;53:667–675.CrossRefPubMedGoogle Scholar
  27. 27.
    Bishnupuri KS, Luo Q, Korzenik JR, et al. Dysregulation of Reg gene expression occurs early in gastrointestinal tumorigenesis and regulates anti-apoptotic genes. Cancer Biol Ther. 2006;5:1714–1720.CrossRefPubMedGoogle Scholar
  28. 28.
    Oue N, Mitani Y, Aung PP, et al. Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. J Pathol. 2005;207:185–198.CrossRefPubMedGoogle Scholar
  29. 29.
    Sentani K, Oue N, Tashiro T, et al. Immunohistochemical staining of Reg IV and claudin-18 is useful in the diagnosis of gastrointestinal signet ring cell carcinoma. Am J Surg Pathol. 2008;32:1182–1189.CrossRefPubMedGoogle Scholar
  30. 30.
    Pankova-Kholmyansky I, Arber N. Reg IV can serve for early diagnosis and therapy. Cancer Biol Ther. 2007;6:123–124.CrossRefPubMedGoogle Scholar
  31. 31.
    Oue N, Sentani K, Noguchi T, et al. Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. Int J Cancer. 2009;125:2383–2392.CrossRefPubMedGoogle Scholar
  32. 32.
    Yamagishi H, Fukui H, Sekikawa A, et al. Expression profile of REG family proteins REG Ialpha and REG IV in advanced gastric cancer: comparison with mucin phenotype and prognostic markers. Mod Pathol. 2009;22:906–913.CrossRefPubMedGoogle Scholar
  33. 33.
    Gu Z, Rubin MA, Yang Y, et al. Reg IV, a promising marker of hormone refractory metastatic prostate cancer. Clin Cancer Res. 2005;11:2237–2243.CrossRefPubMedGoogle Scholar
  34. 34.
    Yasui W, Oue N, Sentani K, Sakamoto N, Motoshita J. Transcriptome dissection of gastric cancer: identification of novel diagnostic and therapeutic targets from pathology specimens. Pathol Int. 2009;59:121–136.CrossRefPubMedGoogle Scholar
  35. 35.
    Kuniyasu H, Oue N, Sasahira T, et al. Reg IV, enhances peritoneal metastasis in gastric carcinomas. Cell Prolif. 2009;42:110–121.CrossRefPubMedGoogle Scholar
  36. 36.
    Mitani Y, Oue N, Matsumura S, et al. Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene. 2007;26:4383–4393.CrossRefPubMedGoogle Scholar
  37. 37.
    Vanderlaag K, Wang W, Fayadat-Dilman L, et al. Regenerating islet-derived family member, 4 modulates multiple receptor tyrosine kinases and mediators of drug resistance in cancer. Int J Cancer. 2012;130:1251–1263.CrossRefPubMedGoogle Scholar
  38. 38.
    Ling ZQ, Li P, Ge MH, et al. Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer. Int J Mol Med. 2011;27:625–635.CrossRefPubMedGoogle Scholar
  39. 39.
    Bishnupuri KS, Luo Q, Sainathan SK, et al. Reg IV regulates normal intestinal and colorectal cancer cell susceptibility to radiation-induced apoptosis. Gastroenterology. 2010;138(2):616–626 (626.e1-2).Google Scholar
  40. 40.
    Glaysher S, Yiannakis D, Gabriel FG, et al. Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). BMC Cancer. 2009;27:300.CrossRefGoogle Scholar
  41. 41.
    Glaysher S, Cree IA. Cell sensitivity assays: the ATP-based tumor chemosensitivity assay. Methods Mol Biol. 2011;731:247–257.CrossRefPubMedGoogle Scholar
  42. 42.
    Nakamura R, Saikawa Y, Wada N, et al. Retrospective analysis of treatment for advanced gastric cancer with peritoneal dissemination. Gan Kagaku Ryoho. 2007;34:1827–1831.Google Scholar
  43. 43.
    Yuan SQ, Zhou ZW, Liang YJ, et al. Correlation of chemosensitivity measured by histoculture drug response assay to expression of multidrug resistance genes and proteins in gastric cancer. Ai Zheng. 2009;28:337–343.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Li-Sha Ying
    • 1
  • Jiang-Liu Yu
    • 1
  • Xiao-Xiao Lu
    • 1
  • Zhi-Qiang Ling
    • 1
  1. 1.Zhejiang Cancer Research Institute, Zhejiang Province Cancer HospitalZhejiang Cancer CenterBanshanqiao District, HangzhouPeople’s Republic of China

Personalised recommendations